Two Cancer Therapies And Ten CDMOs
By Louis Garguilo, Chief Editor, Outsourced Pharma
Vadim Klyushnichenko, PhD, CSCP, VP Pharmaceutical Development and Quality, California Institute for Biomedical Research (Calibr) and The Scripps Research Institute (TSRI), excels at enumeration.
For example, here’s what he tells us about the services he outsources for Calibr’s bispecific small molecule antibody conjugate (SMAC), targeting prostate cancer, that is based on a “unique ADC-type structure optimization enabled by unnatural amino acid technology”:
click on graphic to enlarge
This website uses cookies to ensure you get the best experience on our website. Learn more